Identification of the novel BRCA1 c.2463_2464delTA mutation in two high grade serous ovarian cancer sisters and potential dosage effects implications: a case report.

Background: Ovarian Cancer is one of the leading causes of cancer death among women worldwide and the therapeutic landscape to treat it is constantly evolving. One of the major points of decision for the treatment choice is the presence of some genomic alterations that could confer sensitivity to the new available therapies including inhibitors of poly (ADP-ribose) polymerase (PARPi) with BRCA1 and 2 genes playing the most important role.

Methods And Results: We performed the search for any somatic and/or germline alteration in patient's samples by next generation sequencing (NGS).

TREATMENT OF GASTRIC CANCER ACCORDING TO THE COMPLEXITY OF THE HOSPITAL ONCOLOGY UNIT: ANALYSIS OF 33,774 PATIENTS OVER TWO DECADES.

Background: The hospitals' volume, specialization, availability of all oncological services, and experience in performing complex surgeries have a favorable impact on gastric cancer (GC) treatment.

Aims: The aim of this study was to compare the results of GC treatment according to the type of oncological hospital in the State of São Paulo.

Methods: Patients diagnosed with GC between 2000 and 2022 in qualified hospitals for cancer treatment were evaluated by data extracted from the hospital cancer registry.

Complicated Inguinal Hernia Incidentally Detected on a Radiolabelled Autologous White Blood Cell Scan.

A 73-year-old male with left hip prosthesis infection performed a Tc HMPAO-labelled autologous WBC (WBC) scan to evaluate the response to antibiotic therapy. Since the early planar scan, an area of increased activity was visible extending from the left groin region to the ipsilateral flank. At late planar images, the area progressively focused in the left groin, site of a painful inguinal hernia.

Structural basis for CCR6 modulation by allosteric antagonists.

The CC chemokine receptor 6 (CCR6) is a potential target for chronic inflammatory diseases. Previously, we reported an active CCR6 structure in complex with its cognate chemokine CCL20, revealing the molecular basis of CCR6 activation. Here, we present two inactive CCR6 structures in ternary complexes with different allosteric antagonists, CCR6/SQA1/OXM1 and CCR6/SQA1/OXM2.